Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01949532 · ClinicalTrials.gov registry record · Phase 1
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01949532 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 26 participants.
The verdict
NCT01949532, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they respond differently to the study drug.
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01949532
The ClinicalTrials.gov registry entry for NCT01949532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT01949532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01949532 about?
NCT01949532 is a clinical study titled "Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease". The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they ...
What is the current status of trial NCT01949532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01949532?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01949532?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.